Background: Data are scant regarding access to health care in patients with chronic kidney disease (CKD). We performed descriptive analyses using data from the National Kidney Foundation's Kidney Early Evaluation Program (KEEP), a nationwide health screening program for adults at high risk of CKD.
A
ccess to health care has been defined as "the timely use of personal health services to achieve the best possible outcomes." 1 Barriers to health care access prevent high-quality care from achieving expected positive clinical outcomes. 1 The increasing prevalence of chronic kidney disease (CKD) in the United States has led to a concomitant increase in overall morbidity and mortality related to CKD. Conceivably, improved access to health care in patients with or at risk of CKD could lead to a slowing of this epidemic.
However, to date, the literature for access to health care in kidney disease remains scant and is focused primarily on the dialysis population. Previous reports have shown that poorer access to care in African Americans with CKD compared with whites is linked to higher risk of incident end-stage renal disease 2, 3 and later initiation of dialysis therapy. 4 Fewer studies have examined factors other than race that influence access. Lack of insurance has been reported as a risk factor for CKD progression 5 and poorer control of CKD risk factors, such as hypertension. 6 However, other indicators of health care access, such as difficulty obtaining medical care, type of physician provider, difficulty paying for physician services or medications, and patient-provider interactions, 1 remain unexplored in the population with or at risk of CKD.
Understanding the barriers to CKD care may provide information to allow policy changes that can favorably improve current standards of care, particularly health care delivery and utilization. In addition, health care access for patients with CKD at earlier disease stages, when opportunities to halt or slow disease progression may exist, could emerge as the most important area for intervention. We therefore used data from the Kidney Early Evaluation Program (KEEP) to explore health care access in adults evaluated for CKD. We studied the distribution of various measures of access to medical care across CKD stages and assessed for disparities in these measures across racial and ethnic groups, age groups, and chronic disease states (diabetes, hypertension, and cardiovascular disease [CVD] ) that often accompany CKD.
METHODS

Study Design and Population
KEEP is an ongoing nationwide free health screening program run by the National Kidney Foundation to increase awareness of CKD in people considered at high risk. 7 We identified all KEEP participants 18 years and older from 2000-2010 and excluded those with missing laboratory measurements or receiving renal replacement therapy. The analytic sample after exclusions consisted of 122,502 participants.
Measures of Kidney Function
Laboratory tests were performed on site by trained medical personnel. Serum creatinine was calibrated to the Cleveland Clinic Research Laboratory. Estimated glomerular filtration rate (eGFR) was calculated using the CKD Epidemiology Collaboration (CKD-EPI) equation. 8 CKD stages were defined as follows: stage 1, eGFR Ն90 mL/min/1.73 m 2 and albumin-creatinine ratio (ACR) Ն30 mg/g; stage 2, eGFR of 60-89 mL/min/1.73 m 2 and ACR Ն30 mg/g; stage 3, eGFR of 30-59 mL/min/1.73 m 2 ; stage 4, eGFR of 15-29 mL/min/1.73 m 2 ; and stage 5, eGFR Ͻ15 mL/min/1.73 m 2 . Albuminuria was categorized as normoalbuminuria (ACR Ͻ30 mg/g), microalbuminuria (30-300 mg/g), or macroalbuminuria (Ͼ300 mg/g).
Assessment of Participant Demographics and CKD Risk Factors
Participants were interviewed with a standardized questionnaire. Self-reported demographic characteristics included age, race, and level of education. Hypertension, diabetes, hyperlipidemia, CVD, and stroke were identified by self-report or medication use. In addition, hypertension was defined as an average of twicemeasured blood pressure Ն140/90 mm Hg; diabetes, as measured blood glucose level Ն126 mg/dL (fasting) or Ն200 mg/dL (if last meal within 8 hours); and hyperlipidemia, as measured total cholesterol level Ͼ200 mg/dL or triglyceride level Ͼ150 mg/dL. Family history of CKD was positive if the participant identified any family members with kidney disease or receiving dialysis treatment.
Assessment of Health Care Access
CKD awareness was based on knowledge of kidney disease, urine protein, or urine blood as relayed by a health care professional. Health status was self-reported. Health care utilization was classified based on the last reported visit to any physician. Subjective measure of health care accessibility was ascertained by selfreport of difficulty obtaining medical care on a 4-point Likert scale from extremely difficult to not difficult. We categorized source of medical care as generalist (family practitioner, internist, or geriatrician), nephrologist, other specialist (cardiologist or endocrinologist), other caregiver (obstetrician/gynecologist, physician assistant, or nurse practitioner), or none. Health insurance, type of coverage plan, and insurance benefits for medications were assessed by self-report. Self-paying Ͼ$75/mo for medications was considered a significant burden.
Statistical Analysis
Variables are expressed as mean Ϯ standard deviation or count with proportion, as appropriate. Comparisons between groups were performed with the analysis of variance test for normally distributed continuous variables and 2 test for categorical variables. Variables with missing data are included due to the descriptive nature of the analyses, and numbers of missing data points are reported in table footnotes. All hypothesis testing was 2 tailed, with P Ͻ 0.05 considered statistically significant. Statistical analysis was performed with SAS, version 9.1 (www.sas.com).
RESULTS
Baseline Characteristics
The study population included 122,502 adults without end-stage renal disease who participated in KEEP screenings in 2000-2010 and for whom laboratory data were complete; of these, 27,927 (22.8%) met criteria for CKD (Table 1 ). The distribution of CKD stages was stages 1-2, 8.2%; stage 3, 13.6%; and stages 4-5, 1.0%. Participants with CKD were more likely to be 65 years or older. Racial/ethnic groups were chiefly non-Hispanic white (n ϭ 56,753; 46.3%) and African American (n ϭ 38,379; 31.3%). In the subgroup with CKD stages 3-5, the proportion of non-Hispanic whites was higher (ϳ60%); proportions of non-Hispanic African American and Hispanic participants were lower than in the subgroup without CKD. Education level was more likely to be high school or less for participants with than without CKD. Traditional CVD risk factors, such as hypertension, diabetes, dyslipidemia, prior history of CVD, and tobacco use, were predictably more prevalent in participants with CKD.
Access to Health Care by CKD Stage
Awareness of CKD was low in participants with CKD stages 3 (22.5%) and 4-5 (52.7%; Table 2 ). Participants with CKD were more likely to report fair or poor health status than those without CKD. Health care utilization increased at later CKD stages; ϳ95% of participants with CKD stages 3-5 had visited a physician within the preceding year compared with 83.7% of participants without CKD. More participants with CKD stages 3 and 4-5 reported no difficulty obtaining medical care (47.8% and 41.0%, respectively); participants with no CKD or CKD stages 1-2 were more likely to perceive some difficulty in access to medical care (12.1% and 12.6%, respectively). Less than 6% of participants with CKD stage 3 and Ͻ30% of participants with CKD stages 4-5 reported seeing a nephrologist (alone or with a generalist; Tables 2 and 3 ). At CKD stages 1-2, only ϳ2.5% of participants reported seeing a nephrologist before the screening. Participants with CKD stages 4-5 were on average as likely to see a nephrologist as another specialist (eg, cardiologist or endocrinologist). Participants with CKD stages 3 and 4-5 were more likely to have health insurance (86.8% and 85.0%, respectively) than participants without CKD (75.8%), and Medicare was the most common type of insurance. Although more participants with CKD stages 3 and 4-5 than without CKD reported having insurance benefits and medication coverage, they also reported higher out-of-pocket expenses for medications (Ͼ$75/ mo) than participants without CKD or with early stages of CKD.
Access to Health Care by Race/Ethnicity
Differences in measures of access to health care between non-Hispanic white, non-Hispanic African American, and Hispanic participants at various stages of CKD are shown in Table 4 . Awareness of CKD was lower in African Americans than whites or Hispanics at every stage of CKD. Proportionately more Hispanic participants than white or African American participants reported fair or poor health status at CKD stages 1-2 and 3. Health care utilization with last physician visit in the previous year was Ͼ80%, 90%, and 95% at CKD stages 1-2, 3, and 4-5, respectively, for all racial/ethnic groups, but lower in Hispanic participants with CKD stages 1-2 and 3. Perceived difficulty obtaining medical care was notable for Hispanics, who, compared with white and African American participants, were significantly more likely to report that access was extremely or moderately difficult at all CKD stages. More Hispanic and African American than white participants at all CKD stages reported not having a physician. About a quarter of participants with CKD stages 4-5 had seen a nephrologist (alone or with a generalist) before the KEEP screening, with no significant differences across racial/ethnic groups. White participants were more likely to have health insurance and accompanying medication coverage than African American and Hispanic participants, a difference most pronounced at the earliest (stage 1) and latest (stages 4-5) CKD stages.
Access to Health Care by Age
Awareness of CKD was lower in elderly (age Ն65 years) than younger participants (Table 5) , most notably at CKD stages 4-5 (46.7% and 67.0%, respectively). Elderly participants at all CKD stages were more likely to rate their health status as excellent or good. Younger participants were more likely to rate their health status as fair or poor, especially at CKD stages 4-5; ϳ40% reported fair or poor health status compared with ϳ30% of elderly participants. Elderly participants more commonly (Ͼ95%) than younger participants had seen a physician within the last year, and younger participants at all CKD stages were more likely to report extreme or somewhat/moderate difficulty obtaining medical care. However, elderly participants with CKD stages 3-5, compared with younger counterparts, were less likely to have seen a nephrologist (alone or with a generalist) before the screening. This discrepancy was observed along with greater utilization of specialists (eg, cardiologists and endocrinologists) by elderly participants at all stages of CKD. Rates of health insurance coverage and medication benefits were significantly higher for elderly than younger participants at all CKD stages.
Access to Health Care by Chronic Health Condition
Measures of access to health care at CKD stages 3-5 with accompanying diabetes, hypertension, or CVD are listed in Table 6 ; patterns were similar for each of these chronic conditions. Awareness of CKD was higher in the presence of comorbid diabetes, hypertension, or CVD, and self-rated health status was more likely to be fair or poor. These comorbid conditions were associated with higher utilization of physician visits accompanied by a greater likelihood of reporting that medical care was not very difficult or not difficult to obtain. Participants with diabetes, hypertension, or prior CVD events were more likely than participants without these conditions to have seen a nephrologist in addition to a generalist and/or other specialist, but Ͻ10% reported seeing a nephrologist. 
DISCUSSION
Barriers to health care access affecting patients, physicians, and the health care delivery system complicate the management of almost every chronic disease. In this report, we describe access to health care for participants in KEEP, the largest nationwide CKD screening program. Advanced stages of CKD were associated with greater likelihood of insurance coverage, higher utilization of medical care, and an overall perception of less difficulty obtaining care, yet these measures did not translate to improved self-rated health status. Suboptimal involvement of nephrologists may contribute because Ͻ6% of participants with CKD stage 3 and Ͻ30% with stages 4-5 reported seeing a nephrologist before the screening. African American and Hispanic participants reported more difficulty accessing care than white participants, including lower rates of insurance coverage and physician visits, and these discrepancies persisted across all stages of CKD. Compared with younger participants with CKD, those 65 years or older reported overall better health status in the setting of better insurance coverage and more frequent utilization of generalist and specialist care, although nephrologists were strikingly underutilized across all age groups with CKD. In participants with more advanced stages of CKD, the presence of comorbid diabetes, hypertension, and prior CVD events was associated with improved awareness of CKD and less difficulty obtaining care, including greater utilization of nephrology care.
Awareness of CKD was low overall for KEEP participants; only ϳ20% of participants with CKD stage 3 and 50% with stages 4-5 were aware of their kidney disease. Low awareness of CKD in individuals at stages 3-5 also has been shown in other national cohorts, such as the National Health and Nutrition Examination Survey (NHANES), Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study, and Jackson Heart Study. [9] [10] [11] Similar to findings in these cohorts, CKD awareness in KEEP mildly improved with decreasing eGFR, younger age, and the presence of another chronic health condition. In our study, white participants were more likely than African American participants to be aware of CKD. Importantly, except for younger age, awareness of CKD in KEEP tended to accompany factors associated with easier access to health care, particularly utilization of physician visits.
Health care utilization in KEEP, assessed by the timing of the last physician visit reported by participants and perceived difficulty obtaining health care, was demonstrably higher with increasing severity of CKD. This finding may be attributed to the presence of comorbid conditions, such as prior CVD events, warranting specialist care or hospitalization. In addition, complications of CKD, such as anemia or secondary hyperparathyroidism, may require more frequent Am J Kidney Dis. 2012;59(3)(suppl 2):S5-S15 S11
involvement with a nephrologist alone or in conjunction with a generalist. 12 Hispanic and African American participants were less likely than whites to have seen a physician within the last year and more likely to report difficulty obtaining medical care at all CKD stages. Although cultural beliefs and area racial composition may explain some of these discrepancies, 13 differences in insurance coverage and overall education status also likely have a substantial role. More health care utilization was reported by elderly participants in KEEP than by their younger counterparts, and this divergence cannot be due solely to the higher burden of CKD in the older age group. The presence of comorbid conditions clearly has a role, as does the far greater likelihood of having health insurance (such as Medicare). 14 We found that across all racial/ethnic and age groups and CKD stages, the presence of comorbid conditions led to greater utilization of health care, including more regular physician visits. Although this observation is comforting, the quality of care delivered in these visits and their associated health care costs must be considered. The low rate of nephrologist involvement in this cohort is striking. Overall, only ϳ5% of all KEEP participants with CKD had seen a nephrologist before the screening, and Ͻ30% Am J Kidney Dis. 2012;59(3)(suppl 2):S5-S15 S12 of participants with CKD stages 4-5. Thus, greater utilization of health care does not necessarily translate to a higher rate of interaction with nephrologists. This is particularly troublesome at advanced stages of CKD, when discussions about renal replacement therapy options should be ongoing, and at the earliest stages of CKD (stages 1-2), when implementation of appropriate diagnostic assessments and therapeutic interventions (eg, initiation of renin-angiotensin system blockade, discontinuation of nephrotoxic medications, and designing appropriate diet and exercise regimens) by a nephrologist might have the greatest effect. Although Ͼ85% of participants with CKD stages 1-2 had seen a physician within the past year, only ϳ2.5% had seen a nephrologist. Innovative models of CKD practice, such as nurse-coordinated nephrologist-supervised approaches 15 and multidisciplinary nephrology teams with primary care collaboration 16 to provide optimal and cost-effective care, are being studied, and the hope is that such innovations will increase the presence of nephrologists in patient care. Nephrologist involvement was commonly in collaboration with a generalist and other specialist. Minimal racial/ethnic difference was seen in this pattern of physician comanagement despite a known faster decrease in GFR in African Americans and Hispanics. 17 Slightly fewer elderly participants with CKD stages 3 and 4-5 identified a nephrologist as the source of care, whereas greater involvement of nephrologists was seen in the presence of chronic health conditions. These observations may reflect patterns of nephrologist referral by primary care physicians that may vary depending on their self-efficacy in managing CKD, interaction with nephrologists, and perceived patient barriers to health care access. [18] [19] [20] Nephrologist care is strongly recommended for all patients with CKD stages 4-5 because early nephrology referral is associ- ated with reduced morbidity and mortality when dialysis therapy is started, 21 but not all patients with CKD stage 3 need to be seen by a nephrologist, especially those without proteinuria or at low risk of progression (eg, eGFR consistently Ͼ45 mL/min/1.73 m 2 ). 22 In our cohort, rates of nephrology visits were lower than reported elsewhere, 23 which may be explained in part by study design. KEEP participants volunteer for CKD screening, whereas patients with CKD who already see a nephrologist may not choose to participate. Whether patient-related factors such as poor understanding of the CKD process, denial of disease state, or barriers to nephrology access contributed to the suboptimal or late nephrology involvement is not known. 24 Nevertheless, identification of 1,161 adults with CKD stages 4-5 and 16,684 with CKD stage 3 in a relatively unaware population over 10 years demonstrates the potential influence of a national screening program in making patients and their primary care physicians aware of CKD in time to institute appropriate nephrology involvement.
Our findings have important public health policy implications because they highlight the role of targeted screening activities, such as KEEP, in reducing the burden of CKD-related morbidity and mortality. The screening activity, by raising awareness and facilitating interaction with the medical community, can be viewed as an attempt to improve access to care for individuals with CKD. To date, there has been a surprising paucity of data about access to care in CKD. The Atherosclerosis Risk in Communities (ARIC) Study is the only other large national cohort to report in individuals with CKD a similar trend of decreased health care utilization and insurance coverage in African Americans compared with whites. 25 Such disparities in CKD care across different racial and ethnic groups (including Hispanics, who fare poorly in our cohort), socioeconomic strata, and public versus private health care systems are areas of active investigation. 13, 26, 27 Here, we highlight other groups characterized by poor access to health care, particularly young people with early-stage CKD and all people with CKD and no insurance coverage. The KEEP study population is a high-risk group with high prevalence rates of hypertension, diabetes, CVD, and CKD and good representation of minority subgroups, allowing for analysis of populations at particularly high risk of CKD progression due to poor access to care.
Our study has limitations. Much of the data presented are based on participant recall and thus are subject to error and/or bias. However, the KEEP questionnaire is standardized and data were collected by trained interviewers in an attempt to limit recall bias. KEEP participants are a high-risk population who volunteer for screening, and our findings may not be generalizable to the entire population. Diagnosis of CKD at the screening visit was made by a single blood and urine test for creatinine and proteinuria. In clinical practice, repeated tests over a 3-month period are required to confirm a diagnosis. However, potential measurement errors should be nondifferential and any bias, if present, should be toward the null. Finally, although we were able to study several measures of access to care, other key components, including the efficacy of patient-physician communication, trust and satisfaction in caregivers, waiting times for physician visits, and difficulty with travel to such visits, were not studied and likely contribute to difficulty in health care access.
In conclusion, this descriptive report from the KEEP population highlights differences in CKD awareness, health care utilization, sources of care, health insurance status, and medication coverage across different stages of CKD. We also highlight discrepancies in health care access in patients with CKD by race/ ethnicity, age, and chronic health conditions. These results suggest that a substantial need remains to improve access to medical care in patients with CKD, particularly those who are nonwhite, young, or lack insurance. Involvement of nephrologists at all CKD stages remains poor and does not significantly improve with better access to health care. Thus, screening activities may provide a route to increase awareness of CKD and improve timely utilization of nephrology care, which currently represents the best chance to reduce the global burden of CKD-related morbidity and mortality.
